美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Novo Nordisk A/S B Shares ADRhedged

19.76

-0.0980-0.49%

盤後：19.760.00000.00%16:10 EDT

成交量：5,214.00

成交額：10.36萬

市值：355.72萬

市盈率：- -

高：19.90

開：19.87

低：19.76

收：19.86

52周最高：43.73

52周最低：19.35

股本：18.00萬

流通股本：18.00萬

量比：1.28

換手率：2.90%

股息：0.93

股息率：4.70%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

諾和諾德每周一次基礎胰島素製劑Awiqli獲美國FDA批准

諾和諾德「周製劑」胰島素獲美國FDA批准上市

美股異動丨諾和諾德盤前升逾2%，「周製劑」胰島素在美獲批上市

糖果巨頭CEO加盟減重藥巨頭諾和諾德

諾和諾德任命瑪氏公司CEO為董事會觀察員

減重巨頭決戰線上，「可及性」成關鍵賽點

「減肥神藥」，價格要崩了

減重版司美格魯肽「上新」，更高劑量Wegovy已在美國獲批

21世纪经济报道

凌激副部長兼國際貿易談判副代表會見丹麥諾和諾德公司執行副總裁林意明

南方财经网

諾和諾德(NVO.US)擬在日本拓展減肥藥市場，「曲線入市「瞄準自費患者藍海

諾和諾德據悉正尋求拓寬日本患者獲取減肥藥的渠道

諾和諾德(NVO)股票3月18日盤中下跌3.12%：投資者必看的核心信息

TradingKey中文

Structure肥胖藥物研究結果直追諾和諾德與禮來

反彈50%只是開始？深度覆盤HIMS與藥王的「世紀大和解」

Hims & Hers Health(HIMS)盤前漲8% 日前與諾和諾德建立新的合作伙伴關係

$365億新「藥王」誕生！減肥「神藥」領跑，「自免」新星高漲50%，潛力市場衝刺100億大關

FDA 連發多份 CRL，開年大批新藥上市申請已遭拒

FDA震怒？！諾和諾德瞞報死亡、中風與自殺傾向，司美、利拉魯肽遭警告

諾和諾德遇 FDA 監管提醒，GLP-1 藥物不良事件報告待完善

细胞基因研究圈

諾和諾德旗下「問題」工廠，又一家藥企遭殃

生物制药小编

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVOH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","market":"US","secType":"STK","nameCN":"Novo Nordisk A/S B Shares ADRhedged","latestPrice":19.762,"timestamp":1774641600000,"preClose":19.86,"halted":0,"volume":5214,"hourTrading":{"tag":"盘后","latestPrice":19.762,"preClose":19.762,"latestTime":"16:10 EDT","volume":4,"amount":79.048,"timestamp":1774642204577,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.004934541792547783,"floatShares":180001,"shares":180001,"eps":0,"marketStatus":"休市中","change":-0.098,"latestTime":"03-27 16:00:00 EDT","open":19.87,"high":19.9,"low":19.762,"amount":103572.8717,"amplitude":0.006949,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":19.86,"nav":19.840274,"aum":3571269.160274,"dividendRate":0.046989,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":19.762,"preClose":19.762,"latestTime":"16:10 EDT","volume":4,"amount":79.048,"timestamp":1774642204577,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.275877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","floatShares":180001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.275877,"shares":180001,"dividePrice":0.9286,"high":19.9,"amplitude":0.006949,"preClose":19.86,"low":19.762,"week52Low":19.35,"pbRate":"--","week52High":43.73,"institutionHeld":0,"latestPrice":19.762,"eps":0,"divideRate":0.046989,"volume":5214,"delay":0,"ttmEps":0,"open":19.87,"prevYearClose":27.4362,"prevWeekClose":19.9018,"prevMonthClose":20.176,"prevQuarterClose":27.4362,"fiveDayClose":19.9018,"twentyDayClose":20.176,"sixtyDayClose":27.561},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOH\",params:#limit:5,,,undefined,":[{"date":"2026-03-16","symbol":"NVOH","amount":0.27495,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"NVOH","amount":0.48798,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2025-09-16","symbol":"NVOH","amount":0.16566,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"Novo Nordisk A/S (B Shares) ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-23","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOH\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-16","recordDate":"2025-09-16","paymentDate":"2025-09-23","value":0.16566,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.48798,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.27495,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622538856","title":"諾和諾德每周一次基礎胰島素製劑Awiqli獲美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622538856","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622538856?lang=zh_tw&edition=fundamental","pubTime":"2026-03-28 14:06","pubTimestamp":1774678001,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1093756325.SGD","BK4007","BK4585","LU1093756168.USD","NVOH","NVO","BK4599","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVOX","BK4532","LU0154236417.USD"],"gpt_icon":0},{"id":"2622282640","title":"諾和諾德「周製劑」胰島素獲美國FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2622282640","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622282640?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 19:52","pubTimestamp":1774612372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德宣布，美国食品药品监督管理局(FDA)正式批准其Awiqli(依柯胰岛素注射液:700单位/毫升)上市。该药物主要作为饮食和运动的辅助手段，旨在帮助改善成人2型糖尿病患者的血糖控制。该注射液获批上升后将把每周多达七次的常规基础胰岛素注射大幅缩减至仅需一次，为患者提供了一种革命性的替代方案。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298464","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","BK4007","LU1093756168.USD","BK4532","BK4599","BK4588","LU1093756325.SGD","NVOX","IE00BKVL7J92.USD","NVOH","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4585"],"gpt_icon":0},{"id":"2622846972","title":"美股異動丨諾和諾德盤前升逾2%，「周製劑」胰島素在美獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2622846972","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622846972?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 16:09","pubTimestamp":1774598948,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD","NVO","BK4585","LU0154236417.USD","NVOH","NVOX","BK4007"],"gpt_icon":0},{"id":"2622148138","title":"糖果巨頭CEO加盟減重藥巨頭諾和諾德","url":"https://stock-news.laohu8.com/highlight/detail?id=2622148138","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622148138?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 12:01","pubTimestamp":1774584060,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVOH","BK4588","IE00BKVL7J92.USD","LU0154236417.USD","NVOX","NVO","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4532","BK4007","BK4599","BK4585"],"gpt_icon":0},{"id":"2622610848","title":"諾和諾德任命瑪氏公司CEO為董事會觀察員","url":"https://stock-news.laohu8.com/highlight/detail?id=2622610848","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622610848?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 23:20","pubTimestamp":1774538405,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","BK4532","LU1093756168.USD","BK4588","BK4585","NVO","NVOH","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4599","LU0154236417.USD","NVOX","LU1093756325.SGD"],"gpt_icon":0},{"id":"2622043829","title":"減重巨頭決戰線上，「可及性」成關鍵賽點","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043829","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622043829?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 10:12","pubTimestamp":1774404748,"startTime":"0","endTime":"0","summary":"火爆全球多年的GLP-1减重药赛道，在2025年迎来了历史性转折点。01巨头攻守战，“可及性”成赛点对于如今的诺和诺德而言，药品可及性已然成为其在GLP-1赛道上仅存的竞争优势。显而易见，CagriSema未能在头对头试验中击败替尔泊肽，这场关键战役的失利，直接导致诺和诺德股价在次日暴跌14.64%。一旦Orforglipron顺利上市，诺和诺德独占的口服GLP-1市场将被打破，其仅存的可及性优势也将岌岌可危，甚至可能彻底失守。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774314534087933025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVOX","LLY","BK4599","NVO","LU1093756325.SGD","NVOH","BK4007","BK4532","LU0154236417.USD","LU1093756168.USD","BK4588","BK4585"],"gpt_icon":1},{"id":"2621037044","title":"「減肥神藥」，價格要崩了","url":"https://stock-news.laohu8.com/highlight/detail?id=2621037044","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621037044?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 11:52","pubTimestamp":1774324357,"startTime":"0","endTime":"0","summary":"文｜首席品牌评论2026年3月20日，一个值得写入中国医药产业史的日子。这一天，司美格鲁肽——这款被冠以“减肥神药”之名的全球药王，在中国的核心化合物专利正式到期。专利悬崖如期而至。悬崖之下，是一群早已架好梯子的药企。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774276430002024993","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0154236417.USD","LU1093756168.USD","NVO","BK4599","NVOX","BK4532","BK4007","IE00BZ1G4Q59.USD","NVOH","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","BK4585"],"gpt_icon":1},{"id":"2621067907","title":"減重版司美格魯肽「上新」，更高劑量Wegovy已在美國獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067907","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067907?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 20:57","pubTimestamp":1774270620,"startTime":"0","endTime":"0","summary":"诺和诺德近日宣布，美国食品药品监督管理局（FDA）已批准Wegovy?HD（每周一次司美格鲁肽注射液7.2mg），用于降低过多体重并长期维持减重效果。FDA此前已向Wegovy?HD授予“局长国家优先审批券”（CNPV），从而加快了其审批进程，并凸显其在应对关键患者需求及美国国家健康优先事项方面的潜力。该加速批准基于STEPUP试验项目研究结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603233681185257.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233681185257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1093756325.SGD","LU0820561909.HKD","LU0868494708.USD","LU0823434740.USD","LU0942090050.USD","LU0868494617.USD","LU1069344957.HKD","LU2756315318.SGD","IE00BWXC8680.SGD","NVOX","BK4581","LU0098860793.USD","LU0943347566.SGD","BK4504","LU1914381329.SGD","LU1778281490.HKD","LU1989772840.SGD","NVO","LU1162221912.USD","LU1551013425.SGD","LU2756315664.SGD","LU2361044865.SGD","LU0320765646.SGD","LU0079474960.USD","BK4534","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU0238689110.USD","LU1929549753.HKD","BK4533","LU2461242641.AUD","LU1496350502.SGD","IE00B1XK9C88.USD","LU0354030511.USD","NVOH","SG9999001440.SGD","BK4566","LU2361044949.HKD","LU1496350171.SGD","LU1674673428.USD","LU2361045086.USD","LU1674673691.USD","LU1236620834.HKD","LU0823411888.USD","HD","LU1093756168.USD","LU1551013342.USD","LU0820562030.AUD","LU1989772923.USD","BK4007"],"gpt_icon":0},{"id":"2621953726","title":"凌激副部長兼國際貿易談判副代表會見丹麥諾和諾德公司執行副總裁林意明","url":"https://stock-news.laohu8.com/highlight/detail?id=2621953726","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621953726?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 11:20","pubTimestamp":1774236000,"startTime":"0","endTime":"0","summary":"南方财经3月23日电，据商务部消息，3月20日，商务部副部长兼国际贸易谈判副代表凌激会见丹麦诺和诺德公司执行副总裁林意明，双方围绕企业在华经营情况、中国开放发展机遇等议题进行交流。凌激表示，近年来，中国科技创新能力快速提升，医药健康产业规模不断扩大。中国以新质生产力推动经济高质量发展，已成为全球创新策源地。希望诺和诺德持续深耕中国市场，为建设健康中国作出贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233680260164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4532","LU1093756168.USD","BK4588","BK4585","NVO","NVOH","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4599","LU0154236417.USD","NVOX","LU1093756325.SGD"],"gpt_icon":0},{"id":"2620903249","title":"諾和諾德(NVO.US)擬在日本拓展減肥藥市場，「曲線入市「瞄準自費患者藍海","url":"https://stock-news.laohu8.com/highlight/detail?id=2620903249","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620903249?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 18:25","pubTimestamp":1773915956,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德公司正寻求通过瞄准愿意自费使用Wegovy等胰高血糖素样肽-1药物的患者，来扩大肥胖症治疗在日本的可及性。诺和诺德推动自费医疗的举措，反映了整个行业在渗透率不足的市场扩大治疗的更广泛努力。在肥胖症和罕见病疗法的推动下，诺和诺德日本业务部门去年收入增长了5.4%。\"诺和诺德在日本的努力可能沿袭了其在美国建立的直接面向消费者的销售路径。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVOX","IE00BKVL7J92.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4588","BK4599","BK4532","LU1093756168.USD","LU1093756325.SGD","NVO","NVOH","BK4585","BK4007"],"gpt_icon":1},{"id":"2620431362","title":"諾和諾德據悉正尋求拓寬日本患者獲取減肥藥的渠道","url":"https://stock-news.laohu8.com/highlight/detail?id=2620431362","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620431362?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 17:07","pubTimestamp":1773911228,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4599","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0154236417.USD","BK4588","BK4585","NVOH","BK4007","LU1093756168.USD","BK4532","LU1093756325.SGD","NVO","NVOX"],"gpt_icon":0},{"id":"2620501842","title":"諾和諾德(NVO)股票3月18日盤中下跌3.12%：投資者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2620501842","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620501842?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 23:16","pubTimestamp":1773846978,"startTime":"0","endTime":"0","summary":"• FDA警告信指出司美格鲁肽产品存在违规行为。\n• 竞争加剧以及对研发管线的担忧影响了公司前景。\n• 修订后的2026年营收指引预示销售额将出现下滑。","market":"us","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/Market-Movers/261695175-market-movers-nvo-20260318","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","NVO","LU0154236417.USD","IE00BKVL7J92.USD","BK4007","IE00BZ1G4Q59.USD","NVOH","BK4599","NVOX","BK4532","BK4585","BK4588","LU1093756168.USD","BK7104"],"gpt_icon":1},{"id":"2620476890","title":"Structure肥胖藥物研究結果直追諾和諾德與禮來","url":"https://stock-news.laohu8.com/highlight/detail?id=2620476890","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620476890?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 23:08","pubTimestamp":1773760090,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0154236417.USD","IE0004445239.USD","LU0466842654.USD","LU0823434583.USD","LU0266013472.USD","LU1127390331.HKD","BK4534","LU1974910355.USD","LU2265009873.SGD","LU2112291526.USD","LU1267930730.SGD","LU0471298694.HKD","LU1720051017.SGD","LU0820561818.USD","IE00BJT1NW94.SGD","BK4533","LU0471298777.SGD","LU0823434740.USD","IE00BFSS7M15.SGD","BK4532","LU2756315664.SGD","LU2213496289.HKD","LU0672654240.SGD","LU2264538146.SGD","LU0353189680.USD","LU0432979614.USD","LU2746668461.USD","SG9999014906.USD","LU2089984988.USD","IE0004445015.USD","LU1868836757.USD","LU1623119135.USD","LU0964807845.USD","LU0320765992.SGD","LU2462157665.USD","LU1145028129.USD","IE00BKDWB100.SGD","LU2360106947.USD","SG9999014914.USD","LU2361045086.USD","SG9999018857.SGD","LU0097036916.USD","BK4599","LU2237443978.SGD","LU1548497426.USD","LU2106854487.HKD","SG9999001176.USD","IE00B1XK9C88.USD","LU0708995401.HKD","LU2552382132.HKD","IE00BFSS8Q28.SGD","LU0354030438.USD","LU2023251221.USD","SG9999018865.SGD","LU0203201768.USD","LU2168564495.EUR","IE00BJJMRX11.SGD","LU2896262040.SGD","LU0417517546.SGD","LU1366192091.USD","LU2750360641.GBP","LU2361044865.SGD","LU0096364046.USD","LU0882574055.USD","LU2456880835.USD","IE00B775H168.HKD","ELIL","LU1551013425.SGD","LU2108987350.USD","IE0002141913.USD","BK4516","LU0094547139.USD","LU0640476718.USD","LU2491050154.USD","SG9999015952.SGD","LU1551013342.USD","IE00B4JS1V06.HKD","LU1280957306.USD","LU2237443549.SGD","LU2087625088.SGD","LU1064131342.USD","LU2168564065.EUR","SG9999015986.USD","LU2237443465.HKD","SG9999015978.USD","SG9999014898.SGD","LU0683600562.USD","LU0109394709.USD","LU2237443622.USD","SGXZ81514606.USD","LU0079474960.USD","LU0316494557.USD","LU2750360997.AUD","LU2237438978.USD","LU1035775433.USD","LU2168564149.EUR","LU0256863811.USD","LU2089284900.SGD","LU0354030511.USD","LU2602419157.SGD","LU1989771016.USD","LU2491049909.HKD","LU1069344957.HKD","IE00BZ1G4Q59.USD","LU2271345857.HKD","LU0385154629.USD","LU0256863902.USD","LU2471134523.USD","LU1023059063.AUD","LU1712237335.SGD","LU0456855351.SGD","LU0882574139.USD","LU2063271972.USD","LU2471134952.CNY","LU0106261372.USD","SG9999001176.SGD","LU1061106388.HKD","LU1988902786.USD","BK4007","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU2168563687.JPY","BK4585","LU0238689110.USD","LU0823416689.USD","LU1868836914.USD","BK4581","IE00B7KXQ091.USD","NVOH","IE00BK4W5M84.HKD","LU0889565916.HKD","SG9999014880.SGD","LU2236285917.USD","LU0787776722.HKD","LU1291159041.SGD","LU1814569148.SGD","SGXZ57979304.SGD","GB00BDT5M118.USD","LU1057294990.SGD","LU1720051108.HKD","LU1804176565.USD","SGXZ99366536.SGD","IE0001KFT4U8.USD","IE0005OL40V9.USD","SG9999013999.USD","LU1232071149.USD","LU1629891620.HKD","IE00B1BXHZ80.USD","SGXZ31699556.SGD","LLYZ","LU0289739699.SGD","LU0943347566.SGD","LU1983299246.USD","LU0158827781.USD","LU1323610961.USD","BK4588","SG9999017495.SGD","LU0320765059.SGD","SG9999015945.SGD","LU0122379950.USD","LU2237443382.USD","LU0061475181.USD","LU2357305700.SGD","LU2756315318.SGD","LU2211815571.USD","NVOX","LU0114720955.EUR","IE00BJLML261.HKD","LU0158827948.USD","IE00BWXC8680.SGD","IE00BKVL7J92.USD","LU1093756325.SGD","LU2168564222.USD","LU0234572021.USD","IE00BK4W5L77.USD","IE00BKPKM429.USD","IE00BFTCPJ56.SGD","IE00BN29S564.USD","LU0058720904.USD","LU0689472784.USD","IE0009355771.USD","LLYX","LU1868836591.USD","LU2023250504.SGD","LU2023250330.USD","LU2552382058.USD","LU0006306889.USD","LU2491050071.SGD","LU2746668974.SGD","LU2324357040.USD","LU2111349929.HKD","LU1093756168.USD","ELIS","SGXZ51526630.SGD","LU2552382215.SGD","LU0203202063.USD","IE00B4R5TH58.HKD","LU2471134796.USD","LU0820561909.HKD","LU2461242641.AUD","LU2417539215.USD","LU0323591593.USD","LU1868837300.USD","LU0198837287.USD","LU2361044949.HKD","LU0225283273.USD","LU1868837136.USD","LU1917777945.USD","LU0353189763.USD","IE00BJJMRY28.SGD","LU0786609619.USD","LLII","LU2237443895.HKD","IE00B2B36J28.USD","LU2471134879.HKD","LU0210536198.USD","LU0820562030.AUD","GPCR","LU2089283258.USD","LU2028103732.USD","LU0109391861.USD"],"gpt_icon":0},{"id":"2619019014","title":"反彈50%只是開始？深度覆盤HIMS與藥王的「世紀大和解」","url":"https://stock-news.laohu8.com/highlight/detail?id=2619019014","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619019014?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 21:20","pubTimestamp":1773408035,"startTime":"0","endTime":"0","summary":"在狂热中保持一份清醒","market":"us","thumbnail":"https://img3.gelonghui.com/3c716-ca1a8464-8f16-4866-ab41-c44262ef4bdf.jpg?guru_height=876&guru_width=1605&guru_size=79794","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/3c716-ca1a8464-8f16-4866-ab41-c44262ef4bdf.jpg?guru_height=876&guru_width=1605&guru_size=79794"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4071127","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["IE00BKVL7J92.USD","LU1093756325.SGD","BK4007","IE00BZ1G4Q59.USD","HIMY","BK4599","LU1093756168.USD","NVOH","HIYY","NVOX","HIMS","BK4532","HMYY","BK4585","LU0154236417.USD","BK4588","BK4196"],"gpt_icon":1},{"id":"2618138250","title":"Hims & Hers Health(HIMS)盤前漲8% 日前與諾和諾德建立新的合作伙伴關係","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138250","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138250?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 18:08","pubTimestamp":1773310089,"startTime":"0","endTime":"0","summary":"金吾财讯 | Hims & Hers Health 盘前涨8%，截至发稿，报27.950美元。消息面上，日前，Hims & Hers Health与诺和诺德建立新的合作伙伴关系，专注于提供品牌药物。两家公司于周一表示，诺和诺德已同意在Hims & Hers Health平台上销售其王牌药物Ozempic和Wegovy，其中包括备受欢迎的Wegovy口服片剂。同时，诺和诺德将撤回上个月针对Hims & Hers Health提起的诉讼。作为回报，Hims & Hers Health表示将不再为其仿制版诺和诺德药物投放广告。但如果医生认为患者有必要使用，该公司仍将销售Wegovy和Ozempic的复配版本。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"297963","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","HIMY","BK4532","NVOX","LU0154236417.USD","BK4599","HIMZ","LU1093756168.USD","BK4588","HIMS","IE00BZ1G4Q59.USD","BK4007","BK4196","BK4585","HIYY","IE00BKVL7J92.USD","LU1093756325.SGD","NVOH"],"gpt_icon":0},{"id":"2618917441","title":"$365億新「藥王」誕生！減肥「神藥」領跑，「自免」新星高漲50%，潛力市場衝刺100億大關","url":"https://stock-news.laohu8.com/highlight/detail?id=2618917441","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618917441?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 16:25","pubTimestamp":1773217553,"startTime":"0","endTime":"0","summary":"据梳理，TOP1产品销售额、TOP10产品销售额门槛对比2024年均有提升；替尔泊肽全球销售额超365亿美元，首次斩获“药王”宝座，司美格鲁肽以微弱差距排名第二；抗肿瘤赛道大热，帕博利珠单抗、达雷妥尤单抗、纳武利尤单抗成“三足鼎立”之势；自免新星加速崛起，利生奇珠单抗大涨50%；抗凝老将阿哌沙班坚守TOP4，HIV金标准比克恩丙诺稳健增长。全球新“药王”诞生！其中，BMS贡献约144.43亿美元的销售额，辉瑞的销售额约89.61亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163736a6b79845&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163736a6b79845&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0208291251.USD","LU1037948541.HKD","LU0965508806.USD","SG9999015341.SGD","SG9999002232.USD","NVOH","IE00BLSP4452.SGD","LU0432979614.USD","BK4550","BK4588","LU2112291526.USD","LU0985320562.USD","SG9999001440.SGD","LU1974910355.USD","LU1934455277.USD","LU2125154778.USD","LU1066051225.USD","LU0648001328.SGD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU2361045086.USD","NVO","LU2361044949.HKD","LU0965509283.SGD","LU1941712348.USD","SG9999014567.USD","LU0006306889.USD","LU1116320737.USD","LU1093756168.USD","LU0965509101.SGD","LU0203345920.USD","LU0868494708.USD","LU0320765646.SGD","LU0265550359.USD","LU0980610538.SGD","BK4585","LU1201861249.SGD","BK4516","SGXZ57979304.SGD","LU1929549753.HKD","LU0058720904.USD","LU2106854487.HKD","SG9999015358.SGD","LU2468319806.SGD","SG9999002224.SGD","ABBV","LU0266013472.USD","LU1066053197.SGD","IE00BN8TJ469.HKD","LU2023250843.SGD","LU2361044865.SGD","LU0289739699.SGD","LU1162221912.USD","MRK","LU0130102774.USD","LU0265550946.USD","LU1934455863.HKD","LU1989772923.USD","LU2023250504.SGD","LU1983299246.USD","BK4534","LU1035773651.USD","LU1116320901.HKD","IE00BJJMRZ35.SGD","LU1069347547.HKD","LU0098860793.USD","LU2089984988.USD","LU0070302665.USD","LU0122379950.USD","LU1061106388.HKD","IE0002141913.USD","NVOX","LU0106261372.USD","IE00BKVL7J92.USD","LU1291159041.SGD","IE00BLSP4239.USD","LU0868494617.USD","LU0211331839.USD","SG9999014542.SGD","LU1057294990.SGD","LU1023059063.AUD","SG9999014575.USD","LU1093756325.SGD","LU2324357040.USD","BK4599","LU0320765489.SGD","IE000M9KFDE8.USD","LU0942090050.USD","LU0861579265.USD","BK4007","LU1430594728.SGD","LU1989772840.SGD","LU0477156953.USD","LU1571399168.USD","LU1066051811.HKD","SG9999014559.SGD","LU0203347892.USD","LU1934455194.USD","LU1917777945.USD","SG9999001176.USD","LU0238689110.USD","LU2461242641.AUD","LU1037948897.HKD","IE00B2B36J28.USD","LU0154236417.USD","LU1989771016.USD","IE00B1BXHZ80.USD","IE0009355771.USD","SG9999001176.SGD","BK4532","LU1066051498.USD","LU0234572021.USD","LU1585245621.USD","LU0965509010.AUD","IE00BZ1G4Q59.USD","LU1941712264.USD","LU0130517989.USD","SG9999013999.USD","BK4559","LU1699723380.USD","LU2360032135.SGD","IE00BFTCPJ56.SGD","LLY","IE00B4R5TH58.HKD","BK4533","LU2125154935.USD","IE00BBT3K403.USD"],"gpt_icon":1},{"id":"2618157119","title":"FDA 連發多份 CRL，開年大批新藥上市申請已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618157119?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOH","LU1093756168.USD","BK4121","INCY","IE00BFMHRM44.USD","BK4585","LU1815336091.USD","BK4530","BK4588","LU0128526141.USD","NVO","LU0390134368.USD","LU0154236417.USD","AZN","BK4007","BK4599","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVOX","BK4532","IE00BKVL7J92.USD","LU0029874061.USD","LU0757428866.USD","REGN"],"gpt_icon":0},{"id":"2618153939","title":"FDA震怒？！諾和諾德瞞報死亡、中風與自殺傾向，司美、利拉魯肽遭警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2618153939","media":"药闻天下","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618153939?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 12:33","pubTimestamp":1773203611,"startTime":"0","endTime":"0","summary":"事实上，这并非FDA的突击制裁，而是一场长达一年、最终崩盘的合规拉锯战。在过去整整一年里，诺和诺德信誓旦旦地向FDA提交了多达7次的整改进度报告。根据FDA的警告信披露，诺和诺德的安全数据库中存在大量令人脊背发凉的“漏报”案例：“患者说无关，我们就取消”：在Argus的1331385号病例中，一名使用利拉鲁肽的患者遭遇了中风导致残疾。诺和诺德斥巨资从Catalent手中收购的印第安纳州布卢明顿工厂，近期同样吃到了FDA的警告信。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311143523954825dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311143523954825dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756168.USD","BK4588","BK4007","BK4599","BK4585","LU1093756325.SGD","NVO","NVOH","BK4532","IE00BKVL7J92.USD","NVOX"],"gpt_icon":1},{"id":"2618399032","title":"諾和諾德遇 FDA 監管提醒，GLP-1 藥物不良事件報告待完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2618399032","media":"细胞基因研究圈","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618399032?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 11:58","pubTimestamp":1773201494,"startTime":"0","endTime":"0","summary":"摘要：2026 年 3 月，丹麦药企诺和诺德美国新泽西普兰斯堡总部收到 FDA 正式警告信，核心问题集中在上市后不良药物事件 报告体系的合规性上。涉事产品包含司美格鲁肽等王牌 GLP-1 药物，FDA 直指其报告流程存在多处漏洞，且整改措施未达要求。检查结束当天，FDA 就向诺和诺德出具了Form 483 表格，清晰列出了其在药品副作用监测和报告环节的多项不合规问题。另外，诺和诺德对不良事件的医学审核周期过长，审核效率低下。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311125239a46036e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311125239a46036e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOX","IE00BKVL7J92.USD","BK4144","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4588","BK4599","BK4532","LU1093756168.USD","LU1093756325.SGD","NVO","NVOH","BK4585","BK4590","BK4007"],"gpt_icon":1},{"id":"2618963769","title":"諾和諾德旗下「問題」工廠，又一家藥企遭殃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618963769","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618963769?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 09:20","pubTimestamp":1773192018,"startTime":"0","endTime":"0","summary":"这也是第三家因为该工厂生产设施问题而遭发CRL的药企，其中再生元最为倒霉，2025年，有两款药物皆是因其被拒。2025年10月，同样因为这家工厂的合规性问题，再生元旗下的另一款药物—预填充注射器版本HD Eylea的补充上市申请也遭到拒批，收到FDA的CRL。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","NVOH","BK4585","NVO","BK4588","LU1093756325.SGD","NVOX","IE00BKVL7J92.USD","BK4007","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4532"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}